📊 CMPS Key Takeaways
Investment Thesis
COMPASS Pathways is a pre-revenue stage pharmaceutical company with significant ongoing losses (-$194M net income, -$119.5M operating cash flow) and no commercial revenue generation despite being public since 2020. While the company maintains adequate liquidity with $185.9M cash, the burn rate of ~$120M annually combined with negative returns on assets (-75.9%) and equity (-516%) indicates substantial cash consumption without offsetting revenue, creating critical viability concerns.
CMPS Strengths
- Strong cash position of $185.9M provides runway for operations
- Current ratio of 1.23x indicates near-term liquidity adequacy
- Moderate leverage with debt-to-equity ratio of 0.83x avoids excessive debt burden
CMPS Risks
- No revenue generation despite being a public company, indicating failed commercialization or product development timelines
- Operating cash burn of $119.5M annually will deplete cash reserves in approximately 1.6 years without revenue achievement
- Massive negative profitability metrics (ROE -516%, ROA -75.9%) demonstrate fundamental inability to generate returns on deployed capital
- Pre-clinical stage pharmaceutical company with extremely high execution risk and clinical/regulatory approval uncertainties
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway remaining
- Clinical trial progress and regulatory milestone achievements
- Revenue generation timeline and first commercial product launch success
CMPS Financial Metrics
💡 AI Analyst Insight
COMPASS Pathways plc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CMPS Profitability Ratios
CMPS vs Healthcare Sector
How COMPASS Pathways plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CMPS Balance Sheet & Liquidity
CMPS 5-Year Financial Trend
5-Year Trend Summary: COMPASS Pathways plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.32 indicates the company is currently unprofitable.
CMPS Growth Metrics (YoY)
CMPS Capital Allocation
CMPS SEC Filings
Access official SEC EDGAR filings for COMPASS Pathways plc (CIK: 0001816590)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CMPS
What is the AI rating for CMPS?
COMPASS Pathways plc (CMPS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMPS's key strengths?
Strong cash position of $185.9M provides runway for operations. Current ratio of 1.23x indicates near-term liquidity adequacy.
What are the risks of investing in CMPS?
No revenue generation despite being a public company, indicating failed commercialization or product development timelines. Operating cash burn of $119.5M annually will deplete cash reserves in approximately 1.6 years without revenue achievement.
What is CMPS's revenue and growth?
COMPASS Pathways plc reported revenue of N/A.
Does CMPS pay dividends?
COMPASS Pathways plc does not currently pay dividends.
Where can I find CMPS SEC filings?
Official SEC filings for COMPASS Pathways plc (CIK: 0001816590) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMPS's EPS?
COMPASS Pathways plc has a diluted EPS of $-2.09.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.